P730: EVOLUTION OF IPSS-M RISK CATEGORIES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES FROM DIAGNOSIS TO HYPOMETHYLATING AGENT FAILURE

• Kelly Chien,
• Samuel Urrutia,
• Ziyi LI,
• Rashmi Kanagal-Shamanna,
• Emmanuel Almanza,
• Tareq Abuasab,
• Georgina Gener,
• Alex Bataller,
• Alexandre Bazinet,
• Guillermo Montalban-Bravo,
• Nicholas Short,
• Elias Jabbour,
• Tapan Kadia,
• Farhad Ravandi,
• Gautam Borthakur,
• Danielle Hammond,
• Mahesh Swaminathan,
• Koji Sasaki,
• Sherry Pierce,
• Hagop Kantarjian,
• Guillermo Garcia-Manero

Affiliations

Kelly Chien

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Samuel Urrutia

2 The University of Texas MD Anderson Cancer Center, Cancer Medicine, Houston, United States

Ziyi LI

3 The University of Texas MD Anderson Cancer Center, Biostatistics, Houston, United States

Rashmi Kanagal-Shamanna

4 The University of Texas MD Anderson Cancer Center, Hematopathology, Houston, United States

Emmanuel Almanza

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Tareq Abuasab

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Georgina Gener

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Alex Bataller

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Alexandre Bazinet

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Guillermo Montalban-Bravo

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Nicholas Short

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Elias Jabbour

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Tapan Kadia

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Farhad Ravandi

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Gautam Borthakur

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Danielle Hammond

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Mahesh Swaminathan

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Koji Sasaki

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Sherry Pierce

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Hagop Kantarjian

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Guillermo Garcia-Manero

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States